Abstracts tagged "polymorphism and uveitis"

Abstract Number: 3039 • 2015 ACR/ARHP Annual Meeting
Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease
Toshikatsu Kaburaki¹, Shinji Harihara², Rie Tanaka³, Hiromasa Sawamura⁴, Ai Nishi⁴, Atsushi Hatamochi⁵, Jun Shimizu⁶, Masumi Takeuchi⁷, Shoji Kuwata⁸, Hidetoshi Kawashima⁹ and Fujio Takeuchi¹⁰, ¹Ophthalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Division of Anthropology, Department of Biological Science, The University of Tokyo Graduate School of Science, Tokyo, Japan, ³Department of Ophtalmology, The University of Tokyo Graduate School of Medicine,, Tokyo, Japan, ⁴Department of Ophtalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁵Department of Dermatology, Dokkyo Medical University, Tochigi, Japan, ⁶Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁷Teikyo University Support Center for Women Physicians and Researchers, Teikyo University School of Medicine, Tokyo, Japan, ⁸Third Department of Internal Medicine, Teikyo University Chiba Medical Center, Teikyo University School of Medicine, Chiba, Japan, ⁹Department of Ophthalmology, Jichi Medical University, Tochigi, Japan, ¹⁰Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Behçet's disease (BD) is known to be associated with HLA-B*51:01 and HLA- A*26:01 in many different ethnic groups. Recently, HLA-A*02:07, IL-10 and IL23R-IL12RB polymorphisms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].